Download PDF
Aktuelle Neurologie 2008; 35(9): 450-462
DOI: 10.1055/s-0028-1090039
Fort- und Weiterbildung

© Georg Thieme Verlag KG Stuttgart · New York

Neuromyelitis optica

Neuromyelitis OpticaC.  W.  Ip, H.  Wiendl
Further Information

Publication History

Publication Date:
17 November 2008 (online)

Also available at
    Permissions and Reprints

Weiterbildungsziele

Differenzialdiagnostische Erkennung und diagnostische Einordnung der Neuromyelitis optica und ihrer Unterformen Pathophysiologisches Verständnis der Neuromyelitis optica Verständnis der Rolle von Aquaporin-4-Antikörpern Übersicht über die aktuellen Therapiemöglichkeiten

Literatur

  • 1 Devic E. Subacute myelitis complicated by optic neuritis [in Französisch].  Bull Med. 1894;  8 1033-1034
    PubMedGoogle Scholar
  • 2 Devic E. Acute dorsolumbar myelitis with optic neuritis, autopsy [in Französisch].  Congress Francais Medicine. 1895;  1 434-439
    PubMedGoogle Scholar
  • 3 Albutt T. On the ophtalmoscopic signs of spinal disease.  Lancet. 1870;  1 76-88
    PubMedGoogle Scholar
  • 4 Erb W. Über das Zusammenkommen von Neuritis optica und Myelitis subacuta.  Arch Psychiatr Nervenkr. 1879;  1 146-157
    PubMedGoogle Scholar
  • 5 Phillips P H, Newman N J, Lynn M J. Optic Neuritis in African Americans.  Arch Neurol. 1998;  55 186-192
    CrossrefPubMedGoogle Scholar
  • 6 Gangopadhyay G, Das S, Sarda P. et al . Clinical profile of multiple sclerosis in Bengal.  Neurology India. 1999;  47 18-21
    PubMedGoogle Scholar
  • 7 Kira J. Multiple sclerosis in the Japanese population.  Lancet Neurol. 2003;  2 117-127
    CrossrefPubMedGoogle Scholar
  • 8 Lau K, Wong L, Li L. et al . Epidemiological study of multiple sclerosis in Hong Kong Chinese: questionnaire survey.  Hong Kong Med J. 2002;  8 77-80
    PubMedGoogle Scholar
  • 9 Wingerchuk D M, Hogancamp W F, O'Brien P C. et al . The clinical course of neuromyelitis optica (Devic's syndrome).  Neurology. 1999;  53 1107-1114
    CrossrefPubMedGoogle Scholar
  • 10 Jarius S, Wildemann B. Neuromyelitis optica.  Der Nervenarzt. 2007;  78 1365-1377
    CrossrefPubMedGoogle Scholar
  • 11 Wingerchuk D, Lennon V, Lucchinetti C. et al . The spectrum of neuromyelitis optica.  Lancet Neurol. 2007;  6 805-815
    CrossrefPubMedGoogle Scholar
  • 12 Wingerchuk D M, Lennon V A, Pittock S J. et al . Revised diagnostic criteria for neuromyelitis optica.  Neurology. 2006;  66 1485-1489
    CrossrefPubMedGoogle Scholar
  • 13 Jeffery A, Buncic J. Pediatric Devic's neuromyelitis optica.  J Pediatr Ophthalmol Strabismus. 1996;  33 223-239
    PubMedGoogle Scholar
  • 14 Filley C, Sternberg P, Norenberg M. Neuromyelitis optica in the elderly.  Arch Neurol. 1984;  41 670-672
    PubMedGoogle Scholar
  • 15 McKeon A, Lennon V A, Lotze T. et al . CNS aquaporin-4 autoimmunity in children.  Neurology. 2008;  71 93-100
    CrossrefPubMedGoogle Scholar
  • 16 Weinshenker B, Wingerchuk D, Nakashima I. et al . OSMS is NMO, but not MS: proven clinically and pathologically.  Lancet Neurol. 2006;  5 110-111
    CrossrefPubMedGoogle Scholar
  • 17 Yamasaki K, Horiuchi I, Minohara M. et al . HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies.  Brain. 1999;  122 1689-1696
    CrossrefPubMedGoogle Scholar
  • 18 Pittock S J, Lennon V A, Krecke K. et al . Brain abnormalities in neuromyelitis optica.  Arch Neurol. 2006;  63 390-396
    CrossrefPubMedGoogle Scholar
  • 19 Jarius S, Paul F, Franciotta D. et al . Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica.  Nat Clin Pract Neuro. 2008;  4 202-214
    PubMedGoogle Scholar
  • 20 Misu T, Fujihara K, Nakashima I. et al . Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica.  Neurology. 2005;  65 1479-1482
    CrossrefPubMedGoogle Scholar
  • 21 Wingerchuk D M, Weinshenker B G. Neuromyelitis optica: Clinical predictors of a relapsing course and survival.  Neurology. 2003;  60 848-853
    CrossrefPubMedGoogle Scholar
  • 22 Pittock S, Weinshenker B, Wijdicks E. Mechanical ventilation and tracheostomy in multiple sclerosis.  Neurol Neurosurg Psychiatry. 2004;  75 1331-1333
    CrossrefPubMedGoogle Scholar
  • 23 Howard R, Wiles C, Hirsch N. et al . Respiratory involvement in multiple sclerosis.  Brain. 1992;  115 479-494
    PubMedGoogle Scholar
  • 24 Pittock S. Neuromyelitis optica brain lesions localized at sites of high aquaporin-4 expression.  Arch Neurol. 2006;  63 964-968
    CrossrefPubMedGoogle Scholar
  • 25 Vernant J, Cabre P, Smadja D. et al . Recurrent optic neuromyelitis with endocrinopathies: a new syndrome.  Neurology. 1997;  48 58-64
    PubMedGoogle Scholar
  • 26 Wingerchuk D. A secondary progressive clinical course is uncommon in neuromyelitis optica.  Neurology. 2007;  68 603-605
    CrossrefPubMedGoogle Scholar
  • 27 de Seze J. Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile.  J Neurol Sci. 2002;  197 57-61
    CrossrefPubMedGoogle Scholar
  • 28 Ghezzi A. Clinical characteristics, course and prognosis of relapsing Devic's neuromyelitis optica.  J Neurol. 2004;  251 47-52
    CrossrefPubMedGoogle Scholar
  • 29 Filippi M, Rocca M. MR imaging of Devic's neuromyelitis optica.  Neurol Sci. 2004;  25 371-373
    CrossrefPubMedGoogle Scholar
  • 30 Lycklama G. Spinal-cord MRI in multiple sclerosis.  Lancet Neurol. 2000;  2 555-562
    PubMedGoogle Scholar
  • 31 Tartaglino L. Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters.  Radiology. 1995;  195 725-732
    PubMedGoogle Scholar
  • 32 Cabrera-Gomez J A, Quevedo-Sotolongo L, Gonzalez-Quevedo A. et al . Brain magnetic resonance imaging findings in relapsing neuromyelitis optica.  Mult Scler. 2007;  13 186-192
    CrossrefPubMedGoogle Scholar
  • 33 Poppe A, Lapierre Y, Melançon D. et al . Neuromyelitis optica with hypothalamic involvement.  Mult Scler. 2005;  11 617-621
    CrossrefPubMedGoogle Scholar
  • 34 Ebers G, Paty D. CSF electrophoresis in one thousand patients.  Can J Neurol Sci. 1980;  7 275-280
    PubMedGoogle Scholar
  • 35 McLean B, Luxton R, Thompson E. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications.  Brain. 1990;  113 1269-1289
    CrossrefPubMedGoogle Scholar
  • 36 O'Riordan J. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica.  J Neurol Neurosurg Psychiatry. 1996;  60 382-387
    PubMedGoogle Scholar
  • 37 Bergamaschi R. Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations.  Mult Scler. 2004;  10 2-4
    PubMedGoogle Scholar
  • 38 Melamud L, Madalena L, Facio M. et al . Cerebrospinal fluid findings in Devic's neuromyelitis optica.  Mult Scler. 2006;  12 P246
    PubMedGoogle Scholar
  • 39 Reiber H. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis.  Mult Scler. 1998;  4 111-117
    CrossrefPubMedGoogle Scholar
  • 40 Meinl E. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation.  Ann Neurol. 2006;  59 880-892
    CrossrefPubMedGoogle Scholar
  • 41 Satoh J. Detection of the 14-3-3 protein in the cerebrospinal fluid of Japanese multiple sclerosis patients presenting with severe myelitis.  J Neurol Sci. 2003;  212 11-20
    CrossrefPubMedGoogle Scholar
  • 42 Lennon V. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.  Lancet. 2004;  364 2106-2112
    CrossrefPubMedGoogle Scholar
  • 43 Jarius S. NMO-IgG in the diagnosis of neuromyelitis optica.  Neurology. 2007;  68 1076-1077
    CrossrefPubMedGoogle Scholar
  • 44 Lennon V. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.  J Exp Med. 2005;  202 473-477
    CrossrefPubMedGoogle Scholar
  • 45 Paul F. Antibody to aquaporin-4 in the diagnosis of neuromyelitis optica.  PLoS Med. 2007;  4 e133
    CrossrefPubMedGoogle Scholar
  • 46 Nakashima I. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG.  J Neurol Neurosurg Psychiatry. 2006;  77 1073-1075
    CrossrefPubMedGoogle Scholar
  • 47 Weinstock-Guttman B, Miller C, Yeh E. et al . Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica.  Multiple Sclerosis. 2008;  14 1061-1067
    CrossrefPubMedGoogle Scholar
  • 48 Jung J. Molecular characterization of an aquaporin cDNA from brain: candidate osmoreceptor and regulator of water balance.  Proc Natl Acad Sci USA. 1994;  91 13 052-13 056
    PubMedGoogle Scholar
  • 49 Roemer S F, Parisi J E, Lennon V A. et al . Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.  Brain. 2007;  130 1194-1205
    CrossrefPubMedGoogle Scholar
  • 50 Manley G. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke.  Nat Med. 2000;  6 159-163
    CrossrefPubMedGoogle Scholar
  • 51 Amiry-Moghaddam M. Delayed K+ clearance associated with aquaporin-4 mislocalization: phenotypic defects in brains of [alpha]-syntrophin-null mice.  Proc Natl Acad Sci USA. 2003;  100 13 615-13 620
    PubMedGoogle Scholar
  • 52 Takahashi T, Fujihara K, Nakashima I. et al . Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.  Brain. 2007;  130 1235-1243
    CrossrefPubMedGoogle Scholar
  • 53 Waters P. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally-extensive transverse myelitis.  Arch Neurol. 2008;  65 913-919
    CrossrefPubMedGoogle Scholar
  • 54 Lalive P. Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays.  Neurology. 2006;  67 176-177
    CrossrefPubMedGoogle Scholar
  • 55 Lucchinetti C F, Mandler R N, McGavern D. et al . A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.  Brain. 2002;  125 1450-1461
    CrossrefPubMedGoogle Scholar
  • 56 Holley J. Astrocyte characterization in the multiple sclerosis glial scar.  Neuropathol Appl Neurobiol. 2003;  29 434-444
    CrossrefPubMedGoogle Scholar
  • 57 Ayers M. Early glial responses in murine models of multiple sclerosis.  Neurochem Int. 2004;  45 409-419
    CrossrefPubMedGoogle Scholar
  • 58 Pittock S, Lennon V. Aquaporin-4 autoantibodies in a paraneoplastic context.  Arch Neurol. 2008;  65 629-632
    CrossrefPubMedGoogle Scholar
  • 59 Misu T, Fujihara K, Kakita A. et al . Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.  Brain. 2007;  130 1224-1234
    CrossrefPubMedGoogle Scholar
  • 60 Matiello M, Lennon V A, Jacob A. et al . NMO-IgG predicts the outcome of recurrent optic neuritis.  Neurology. 2008;  70 2197-2200
    CrossrefPubMedGoogle Scholar
  • 61 Paty D, Oger J, Kastrukoff L. et al . MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT.  Neurology. 1988;  38 180-185
    CrossrefPubMedGoogle Scholar
  • 62 Barkhof F, Filippi M, Miller D. et al . Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.  Brain. 1997;  120 2059-2069
    CrossrefPubMedGoogle Scholar
  • 63 Wingerchuk D. Diagnosis and treatment of neuromyelitis optica.  Neurologist. 2007;  13 2-11
    CrossrefPubMedGoogle Scholar
  • 64 Weinshenker B, Wingerchuk D, Vukusic S. et al . Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis.  Ann Neurol. 2006;  59 566-569
    CrossrefPubMedGoogle Scholar
  • 65 Jacobi C. Neuromyelitis optica (Devic's syndrome) as first manifestation of systemic lupus erythematosus.  Lupus. 2006;  15 107-109
    CrossrefPubMedGoogle Scholar
  • 66 Weinshenker B, Pittock S, de Seze J. et al . The relationship between neuromyelitis optica and systemic auto-immune disease.  Mult Scler. 2006;  12 O79
    PubMedGoogle Scholar
  • 67 Pittock S, Lennon V, de Seze J. et al . Neuromyelitis optica and non organ-specific autoimmunity.  Arch Neurol. 2008;  65 78-83
    CrossrefPubMedGoogle Scholar
  • 68 Wingerchuk D, Weinshenker B. Neuromyelitis optica.  Curr Treat Options Neurol. 2008;  10 55-66
    CrossrefPubMedGoogle Scholar
  • 69 Beck R W, Cleary P A, Trobe J D. et al . The Effect of Corticosteroids for Acute Optic Neuritis on the Subsequent Development of Multiple Sclerosis.  N Engl J Med. 1993;  329 1764-1769
    CrossrefPubMedGoogle Scholar
  • 70 Keegan M, Pineda A A, McClelland R L. et al . Plasma exchange for severe attacks of CNS demyelination: Predictors of response.  Neurology. 2002;  58 143-146
    CrossrefPubMedGoogle Scholar
  • 71 Papeix C, Vidal J-S, de Seze J. et al . Immunosuppressive therapy is more effective than interferon in neuromyelitis optica.  Multiple Sclerosis. 2007;  13 256-259
    CrossrefPubMedGoogle Scholar
  • 72 Warabi Y, Matsumoto Y, Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination.  J Neurol Sci. 2007;  252 57-61
    CrossrefPubMedGoogle Scholar
  • 73 Saida T, Tashiro K, Itoyama Y. et al . Interferon beta-1b is effective in Japanese RRMS patients: A randomized, multicenter study.  Neurology. 2005;  64 621-630
    PubMedGoogle Scholar
  • 74 Bergamaschi R. Glatiramer acetate treatment in Devic's neuromyelitis optica.  Brain. 2003;  126 E1
    CrossrefPubMedGoogle Scholar
  • 75 Gartzen K, Limmroth V, Putzki N. Relapsing neuromyelitis optica responsive to glatiramer acetate treatment.  Eur J Neurol. 2007;  14 12-13
    CrossrefPubMedGoogle Scholar
  • 76 Watanabe S, Misu T, Miyazawa I. et al . Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis.  Mult Scler. 2007;  13 968-974
    CrossrefPubMedGoogle Scholar
  • 77 Mandler R. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine.  Neurology. 1998;  51 1219-1220
    CrossrefPubMedGoogle Scholar
  • 78 Cree B AC, Lamb S, Morgan K. et al . An open label study of the effects of rituximab in neuromyelitis optica.  Neurology. 2005;  64 1270-1272
    CrossrefPubMedGoogle Scholar
  • 79 Jacob A, Weinshenker B G, Violich I. et al . Treatment of Neuromyelitis Optica With Rituximab: Retrospective Analysis of 25 Patients.  Arch Neurol. 2008;  65 noc80069
    PubMedGoogle Scholar
  • 80 Chan A, Weilbach F, Toyka K. et al . Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients.  Clin Exp Immunol. 2005;  139 152-158
    CrossrefPubMedGoogle Scholar
  • 81 Neuhaus O, Wiendl H, Kieseier B. et al . Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro.  J Neuroimmunol. 2005;  1–2 128-137
    PubMedGoogle Scholar
  • 82 Weinstock-Guttman B, Ramanathan M, Lincoff N. et al . Study of Mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).  Arch Neurol. 2006;  63 957-963
    CrossrefPubMedGoogle Scholar
  • 83 Falcini F, Trapani S, Ricci L. et al . Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment.  Rheumatology. 2006;  45 913-915
    CrossrefPubMedGoogle Scholar
  • 84 Bakker J, Metz L. Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG).  Can J Neurol Sci. 2004;  31 265-267
    PubMedGoogle Scholar

Prof. H. Wiendl

Klinische Forschungsgruppe für MS und Neuroimmunologie, Abteilung Neurologie, Universität Würzburg

Josef-Schneider-Str. 11

97080 Würzburg

Email: heinz.wiendl@klinik.uni-wuerzburg.de

      >